In the second quarter of 2018, real US drug prices declined 5.8%, and it may be thanks to co-payment accumulators; more than 25 patient and consumer groups released a statement that said a new bill to protect Americans with pre-existing conditions would not be sufficient; the Department of Justice has issued a warning to cities planning to set up supervised injection sites as a tactic to curb opioid overdose deaths.
In the second quarter of 2018, real US drug prices declined 5.8%, and it may be thanks to a new tactic by insurers. According to Reuters, co-payment accumulator programs are forcing drug companies to assist patients with co-pays, while they receive less revenue on sales. However, the tactic is not necessarily translating into savings for patients—employers and payers are more likely to benefit. The co-pay accumulator prevents coupons from counting toward a patient’s deductible.
More than 25 patient and consumer groups released a statement that said a new bill to protect Americans with pre-existing conditions would not be sufficient. The legislation was introduced by 10 Republican senators with the aim of protecting people with pre-existing conditions if an ongoing lawsuit against the Affordable Care Act is successful, reported The Hill. According to the statement, the bill does not actually ban pre-existing condition exclusions. In addition, the bill “would remove rating restrictions based on age, gender, tobacco use, or occupation.” Some of the co-signers on the statement include American Cancer Society Cancer Action Network, American Diabetes Association, Leukemia & Lymphoma Society, National Health Council, and Susan G. Komen.
New York City, San Francisco, Philadelphia, and other cities have plans to set up supervised injection sites as an approach to combat the nationwide opioid epidemic, but the Department of Justice has issued a warning to these cities over the plans. The Washington Post reported that the federal government has taken the position the setting up such sites violates a law that criminalizes places where illegal drugs are knowingly used. However, the cities, and other advocates, argue the sites can save the lives of people who would otherwise use the drugs in less safe and sanitary conditions. The supervised sites are monitored by staffers who have naloxone in the event of an opioid overdose.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen